BDBM398249 4-chloro-N-((4, 4-difluorocyclohexyl)methyl)-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-indole-3-carboxamide::US10323000, Compound 189::US10676433, Compound 189

SMILES FC1(F)CCC(CNC(=O)c2cn(CCN3CCCC3=O)c3cccc(Cl)c23)CC1

InChI Key InChIKey=BLBOFCVFAJJLMF-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 398249   

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398249(US10323000, Compound 189 | 4-chloro-N-((4, 4-diflu...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Merck Patent

US Patent
LigandPNGBDBM398249(US10323000, Compound 189 | 4-chloro-N-((4, 4-diflu...)
Affinity DataIC50: 55nMAssay Description:Agonist-induced pore formation was determined by measuring cellular uptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7 receptor....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398249(US10323000, Compound 189 | 4-chloro-N-((4, 4-diflu...)
Affinity DataIC50: 300nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2020
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Merck Patent

US Patent
LigandPNGBDBM398249(US10323000, Compound 189 | 4-chloro-N-((4, 4-diflu...)
Affinity DataIC50: 300nMAssay Description:The activation of P2X7 by ATP leads to a fast transient activation of cells resulting in influx of Ca2+ followed by conversion of pro-IL-1β to a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent